EGFR and non-small cell lung carcinoma: For example, erlotinib, the first TKI for NSCLC patients who carry the L858R mutation in EGFR, dramatically inhibited the proliferation of cancer cells, thereby shrinking tumors and extending the lives of patients when concurrently used with chemotherapeutic drugs [37].